Literature DB >> 22112841

Metal complexes as inhibitors of the 26S proteasome in tumor cells.

Cláudio N Verani1.   

Abstract

The ubiquitin/proteasome pathway is the main mechanism available for eukaryotic cells to eliminate defective proteins and enzymes. Tumor cells -particularly those in solid tumors such as prostate cancer- seem to display increased proteasomal activity associated to cell growth. When such activity is inhibited apoptotic cell death takes place. Thus, the understanding of the chemical mechanisms by which this inhibition occurs is relevant to the development of new therapeutic antineoplastic agents. Here a short review is presented on the synthesis, characterization, and activity of metal-containing species with asymmetric ligands containing the methylpyridin-amino-methylphenol moiety. These complexes were scrupulously investigated structurally and spectroscopically, and have been shown to inhibit the chymotrypsin-like activity of the 20S and 26S proteasome in vitro and in vivo. Recent developments in the understanding of such inhibition are discussed and point out to the influence exerted by ligand substituents, the electronic configurations and charges of the metal ion, and the role of counterions.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112841     DOI: 10.1016/j.jinorgbio.2011.09.003

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  13 in total

1.  Physical properties, ligand substitution reactions, and biological activity of Co(iii)-Schiff base complexes.

Authors:  A Paden King; Hendryck A Gellineau; Samantha N MacMillan; Justin J Wilson
Journal:  Dalton Trans       Date:  2019-05-07       Impact factor: 4.390

2.  Association of metals and proteasome activity in erythrocytes of prostate cancer patients and controls.

Authors:  Christine Neslund-Dudas; Bharati Mitra; Ashoka Kandegedara; Di Chen; Sara Schmitt; Min Shen; Qiuzhi Cui; Benjamin A Rybicki; Q Ping Dou
Journal:  Biol Trace Elem Res       Date:  2012-03-16       Impact factor: 3.738

3.  A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.

Authors:  C Zhao; X Chen; D Zang; X Lan; S Liao; C Yang; P Zhang; J Wu; X Li; N Liu; Y Liao; H Huang; X Shi; L Jiang; X Liu; Z He; Q P Dou; X Wang; J Liu
Journal:  Oncogene       Date:  2016-04-18       Impact factor: 9.867

Review 4.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Authors:  Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2015-06-16       Impact factor: 6.674

5.  Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Authors:  Claire L Soave; Tracey Guerin; Jinbao Liu; Q Ping Dou
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

6.  Transcriptome sequencing (RNA-seq) analysis of the effects of metal nanoparticle exposure on the transcriptome of Chlamydomonas reinhardtii.

Authors:  Dana F Simon; Rute F Domingos; Charles Hauser; Colin M Hutchins; William Zerges; Kevin J Wilkinson
Journal:  Appl Environ Microbiol       Date:  2013-05-31       Impact factor: 4.792

7.  Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.

Authors:  Xiaoying Lan; Chong Zhao; Xin Chen; Peiquan Zhang; Dan Zang; Jinjie Wu; Jinghong Chen; Huidan Long; Li Yang; Hongbiao Huang; Bing Z Carter; Xuejun Wang; Xianping Shi; Jinbao Liu
Journal:  J Hematol Oncol       Date:  2016-11-25       Impact factor: 17.388

Review 8.  A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?

Authors:  Vasiliki D Papakonstantinou; Nefeli Lagopati; Effie C Tsilibary; Constantinos A Demopoulos; Athanassios I Philippopoulos
Journal:  Bioinorg Chem Appl       Date:  2017-03-28       Impact factor: 7.778

9.  A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.

Authors:  Ningning Liu; Chunjiao Liu; Xiaofen Li; Siyan Liao; Wenbin Song; Changshan Yang; Chong Zhao; Hongbiao Huang; Lixia Guan; Peiquan Zhang; Shouting Liu; Xianliang Hua; Xin Chen; Ping Zhou; Xiaoying Lan; Songgang Yi; Shunqing Wang; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Sci Rep       Date:  2014-06-10       Impact factor: 4.379

10.  Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.

Authors:  Ningning Liu; Xiaofen Li; Hongbiao Huang; Chong Zhao; Siyan Liao; Changshan Yang; Shouting Liu; Wenbin Song; Xiaoyu Lu; Xiaoying Lan; Xin Chen; Songgang Yi; Li Xu; Lili Jiang; Canguo Zhao; Xiaoxian Dong; Ping Zhou; Shujue Li; Shunqing Wang; Xianping Shi; Ping Q Dou; Xuejun Wang; Jinbao Liu
Journal:  Oncotarget       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.